Hero

Celyad Presents Update on CYAD-01 Solid Tumor Clinical Program at the SITC 33rd Annual Meeting

1

Celyad Presents Update on CYAD-01 Solid Tumor Clinical Program at the SITC 33rd Annual Meeting

Celyad to Present New CYAD-01 Data from THINK Study in Relapsed/Refractory Acute Myeloid Leukemia at 2018 ASH Annual Meeting

2

Celyad to Present New CYAD-01 Data from THINK Study in Relapsed/Refractory Acute Myeloid Leukemia at 2018 ASH Annual Meeting

About Celyad

Making the Impossible Possible

Celyad is a clinical-stage biopharmaceutical that is developing next generation CAR-T NK cell-based immunotherapies for cancer treatment.

Latest News

Celyad to Participate at Upcoming Healthcare Conferences

Celyad to Participate at Upcoming Healthcare Conferences

Celyad Presents Update on CYAD-01 Solid Tumor Clinical Program at the SITC 33rd Annual Meeting

Celyad Presents Update on CYAD-01 Solid Tumor Clinical Program at the SITC 33rd Annual Meeting

Celyad to Present New CYAD-01 Data from THINK Study in Relapsed/Refractory Acute Myeloid Leukemia at 2018 ASH Annual Meeting

Celyad to Present New CYAD-01 Data from THINK Study in Relapsed/Refractory Acute Myeloid Leukemia at 2018 ASH Annual Meeting

Discover all news

Carousel

Social Feed

"Les données présentées lors du congrès @sitcancer démontrent qu’il existe de l’espoir pour l’utilisation de la tec… https://t.co/t6DJg9qPZT

20 hours ago

"Les données présentées lors du congrès @sitcancer démontrent qu’il existe de l’espoir pour l’utilisation de la tec… https://t.co/t6DJg9qPZT

RT @Labiotech_eu: “We feel that the #CAR-T therapy does have a potential anti-tumor effect” #biotech #solidtumors @CelyadSA https://t.co/eO…

21 hours ago

RT @Labiotech_eu: “We feel that the #CAR-T therapy does have a potential anti-tumor effect” #biotech #solidtumors @CelyadSA https://t.co/eO…

Celyad to Participate at Upcoming Healthcare Conferences https://t.co/nbgQMGzEsR https://t.co/ywstK34sXR

1 day ago

Celyad to Participate at Upcoming Healthcare Conferences https://t.co/nbgQMGzEsR https://t.co/ywstK34sXR

@SimonBornschein Congrats to the team!

5 days ago

@SimonBornschein Congrats to the team!

"Les données présentées lors du congrès @sitcancer démontrent qu’il existe de l’espoir pour l’utilisation de la tec… https://t.co/t6DJg9qPZT

20 hours ago

"Les données présentées lors du congrès @sitcancer démontrent qu’il existe de l’espoir pour l’utilisation de la tec… https://t.co/t6DJg9qPZT

RT @Labiotech_eu: “We feel that the #CAR-T therapy does have a potential anti-tumor effect” #biotech #solidtumors @CelyadSA https://t.co/eO…

21 hours ago

RT @Labiotech_eu: “We feel that the #CAR-T therapy does have a potential anti-tumor effect” #biotech #solidtumors @CelyadSA https://t.co/eO…

Celyad to Participate at Upcoming Healthcare Conferences https://t.co/nbgQMGzEsR https://t.co/ywstK34sXR

1 day ago

Celyad to Participate at Upcoming Healthcare Conferences https://t.co/nbgQMGzEsR https://t.co/ywstK34sXR

@SimonBornschein Congrats to the team!

5 days ago

@SimonBornschein Congrats to the team!